VANCOUVER, British Columbia, June 18, 2021 (GLOBE NEWSWIRE) – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company“) is pleased to announce that it has retained Smart & Biggar LLP (“Smart and Biggar“) to manage all intellectual property deposits for Akome Biotech Ltd. (“Akome“) And Vocan Biotechnologies Inc. (“Vocan“).

Smart & Biggar is the largest and highest ranked intellectual property law firm in Canada. Smart and Biggar’s award-winning IP team has helped the most successful businesses in Canada and around the world protect, enforce and use their IP rights to grow their businesses. For innovative pharmaceutical and life sciences companies, they offer specialized expertise in the enforcement of intellectual property rights in Canada through their combined strengths in prosecution, regulation and litigation. With more than 100 attorneys, patent agents and trademark agents, Smart and Biggar offer legal expertise and technological knowledge in a wide range of industries and scientific and technical disciplines, with leaders in all fields.

We are very happy to work with the largest intellectual property firm in Canada, who will assist us with all of our PCT filings, which will protect and strengthen our intellectual property. The arena of psychedelic medicine is still in its infancy, with many different companies working on commercially viable psychedelic drug solutions. At Core One, we believe we are at the forefront of some revolutionary psychedelic solutions that will be of great value in the future. The engagement of Canada’s largest IP firm is the first step in creating and protecting the value we intend to create for all shareholders,Said Joel Shacker, CEO of the company.

About Core One Labs Inc.

Core One is a biotechnology and life science technology research company focused on bringing psychedelic drugs to market through novel delivery systems and psychedelic-assisted psychotherapy. Core One has developed a patent pending thin film oral tape (the “Technology”) Which dissolves instantly when placed in the mouth and delivers organic molecules in precise amounts into the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also owns a stake in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, the R&D related to psychedelic treatments and new drug therapies, the Company intends to obtain regulatory research approval for the advancement of treatments derived from psychedelics. for mental health disorders.

Core One Labs Inc.
Joel shacker
Chief executive officer

[email protected]


The Canadian Securities Exchange has not reviewed and accepts no responsibility for the adequacy or accuracy of the contents of this press release.

The information contained in this press release contains forward-looking statements based on assumptions as of the date of this press release. These statements reflect the current estimates, beliefs, intentions and expectations of management. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of important factors, many of which are beyond the control of the Company. These factors include, among others: risks and uncertainties associated with the Company’s limited operating history and the need to comply with strict regulatory regulations. Therefore, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Unless required by applicable securities legislation, the Company assumes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offense to possess substances under the Controlled Drugs and Substances Act (Canada) without prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One has no direct or indirect involvement in the illegal sale, production or distribution of psychedelics in the jurisdictions in which it operates. While Core One believes that psychedelics can be used to treat certain medical conditions, it does not advocate legalizing psychedelics for recreational purposes. Core One does not deal with psychedelics except in laboratory and clinical trials conducted under approved regulatory frameworks.


Leave a Reply

Your email address will not be published.